Trial Profile

An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CCX 872 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Amgen; ChemoCentryx

Most Recent Events

14 Mar 2022 Status changed from active, no longer recruiting to completed.
14 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
14 Aug 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com